In San Diego, a company that helps over a million people live without the ritual of finger pricks has broken through a long-tested ceiling — in both its stock price and its public presence. Dexcom, founded in 1999 to reimagine diabetes management, posted 113% earnings growth in early 2023 and amplified its reach through a Super Bowl appearance featuring Nick Jonas, a celebrity who carries the story personally. The convergence of strong fundamentals, technical momentum, and a growing awareness of diabetes as both a physical and mental health challenge suggests this is a company finding its stri
Dexcom Stock Breaks Resistance as Diabetes Leader Posts 113% Earnings Growth
The company's technology helps over 1 million people with diabetes manage their condition without finger pricks, improving quality of life and mental health outcomes.
More than a million people worldwide rely on this technology daily.
Mark
Why does a diabetes company's stock chart matter to anyone outside of Wall Street?
Mimi
Because the stock price reflects whether the market believes the company can keep growing and serving more patients. When Dexcom breaks through resistance on strong volume, it suggests institutional investors are confident in the earnings growth we're seeing—113 percent in the last quarter.
Mark
That's a huge number. What changed to make earnings jump that much?
Mimi
The company had struggled with inconsistent profitability for a while, but it's bounced back in the last three quarters. The revenue is steady—18 percent growth year-over-year—but the bottom line is accelerating. That suggests they're getting more efficient at converting sales into actual profit.
Mark
And the Nick Jonas Super Bowl ad—is that just marketing, or does it actually move the needle?
Mimi
It's both. Functionally, it raises awareness of the G7 system among people who might not know continuous glucose monitoring exists. But it also signals that Dexcom is confident enough to spend that kind of money on brand building. Companies don't run Super Bowl ads unless they believe they can handle the demand that follows.
Mark
A million people using this every day—that's a real market.
Mimi
It is. And the market is still growing. The company is in 197 industry groups tracked, and it's tied for the top rating in its own category. That doesn't happen by accident.
Mark
What's the risk here?
Mimi
Stock breakouts don't always hold. The relative strength line is climbing, which is a good sign, but if earnings disappoint in the next quarter or two, the stock could fall back below that resistance line. The forecast for Q2 is 33 percent EPS growth—if they miss that, the momentum breaks.
Mark
So we're watching to see if they can sustain this.
Mimi
Exactly. The chart is saying the market believes they will. The next earnings report will tell us if that belief is justified.
O Pulso
- After months of testing resistance near 122, Dexcom's stock finally broke through 126.44 on heavy volume — a signal technical analysts treat as a meaningful shift in momentum.
- A 113% surge in earnings per share, paired with raised full-year guidance, silenced doubts about whether the company's bottom line could match its top-line growth story.
- A Super Bowl commercial featuring Nick Jonas — himself a person with diabetes and a paid sponsor — brought the G7 glucose monitor into living rooms that financial disclosures never could reach.
- Analysts are now projecting 33% EPS growth for Q2 and 25% for the full year, with the stock's relative strength line beginning to climb toward a new 52-week high.
- Beyond the charts, Dexcom is framing its mission in human terms — releasing research on diabetes and mental health, and hosting free Puppy Yoga classes in London during Diabetes Awareness Week.
In San Diego, a company that helps over a million people live without the ritual of finger pricks has broken through a long-tested ceiling — in both its stock price and its public presence. Dexcom, founded in 1999 to reimagine diabetes management, posted 113% earnings growth in early 2023 and amplified its reach through a Super Bowl appearance featuring Nick Jonas, a celebrity who carries the story personally. The convergence of strong fundamentals, technical momentum, and a growing awareness of diabetes as both a physical and mental health challenge suggests this is a company finding its stride at a moment when the world is paying closer attention.
Dexcom, the San Diego-based diabetes technology company, cleared a stubborn stock resistance level this week, entering what analysts call a buy zone after months of testing the 122 mark. The breakout came on strong volume and was backed by something more than chart patterns — a company visibly gaining momentum on multiple fronts.
In the first quarter of 2023, Dexcom reported 113% earnings per share growth on revenue of $741.5 million, beating Wall Street expectations and raising its full-year guidance. Analysts now forecast 33% EPS growth for Q2 and 25% for the full year — a significant shift after several quarters of uneven bottom-line performance. Sales growth over the past eight quarters has ranged steadily between 17 and 32 percent.
At the center of the story is the Dexcom G7, a continuous glucose monitoring system that lets people with diabetes track blood sugar in real time via smartphone or smartwatch — no finger pricks required. More than a million people rely on it daily. In February, the company ran only its second-ever Super Bowl commercial, featuring Nick Jonas, a multiplatinum artist and paid sponsor who lives with diabetes himself. The ad brought the product to an audience no earnings report could reach.
Founded in 1999 and now employing more than 8,000 people globally, Dexcom holds a 98 Composite Rating from IBD Stock Checkup — tied for the top spot in the medical products industry group. The company has also cited the CHIPS Act as meaningful to its operations, noting that semiconductor technology underpins its monitoring systems.
As Diabetes Awareness Week began in the United Kingdom, Dexcom released research showing that 84% of people believe diabetes negatively affects mental health, and announced free Puppy Yoga classes in London as a gesture toward community wellness. It is a small but telling detail — a company learning to speak not just to investors, but to the people its technology is meant to serve.
Dexcom, the San Diego-based diabetes management company, has broken through a stubborn ceiling in its stock price this week, clearing resistance at 126.44 and entering what technical analysts call a buy zone. The move came on strong volume and caps months of the stock testing a line of resistance around the 122 mark. What makes this moment worth watching is not just the chart pattern, but what's happening inside the company itself.
In the first quarter of 2023, Dexcom reported earnings per share growth of 113 percent, reaching 17 cents per share on revenue of $741.5 million—an 18 percent year-over-year increase. The company beat Wall Street expectations and raised its full-year guidance. This marks a significant turnaround after several quarters of inconsistent bottom-line performance. Analysts are now forecasting 33 percent EPS growth for the second quarter and a 25 percent gain for the full year.
The company's core product is the Dexcom G7, a continuous glucose monitoring system that allows people with diabetes to track their blood sugar in real time on a smartphone or smartwatch without the need for finger pricks. More than a million people worldwide rely on this technology daily. In February, Dexcom amplified its visibility by running a Super Bowl commercial featuring Nick Jonas, the multiplatinum recording artist who is also a paid sponsor of the company. The ad was only the company's second Super Bowl appearance ever.
Dexcom's growth trajectory has been steady if not spectacular. Over the past eight quarters, sales growth has ranged between 17 and 32 percent. The company, founded in 1999, now employs more than 8,000 people globally. Its financial strength is reflected in a 98 Composite Rating from IBD Stock Checkup, tying it with Penumbra for the top spot in the medical products industry group, which itself ranks 32nd out of 197 industry groups tracked.
The timing of the stock breakout aligns with broader tailwinds. In 2022, President Joe Biden signed the CHIPS Act into law—legislation that Dexcom had specifically cited in its advocacy, noting that semiconductor technology is fundamental to its continuous glucose monitoring systems. The company framed the issue in human terms: the technology helps people with diabetes manage their condition more effectively.
Beyond the financial metrics, Dexcom has been positioning itself as a company that understands the broader health dimensions of diabetes. Earlier this week, as Diabetes Awareness Week began in the United Kingdom, the company released research showing that 84 percent of people agree that having diabetes can negatively impact mental health. In response, Dexcom announced it would host free Puppy Yoga classes in London to promote mental wellness within the diabetes community.
The stock's technical picture suggests momentum is building. The relative strength line, which had moved sideways during the pattern formation, has begun to climb toward a new 52-week high. The stock rose nearly 5 percent for the week and has posted a string of heavy-volume up days since the end of May. For investors watching the medical device sector, Dexcom's breakout and the convergence of strong earnings, product visibility, and technical strength are worth monitoring closely.
Citações Notáveis
Semiconductor technology enables our continuous glucose monitoring systems, helping the lives of more than a million people with diabetes around the world who depend on Dexcom CGM every day.— Dexcom, in advocacy for the CHIPS Act (2022)
84% of people agree that having diabetes can negatively impact mental health.— Dexcom research released during Diabetes Awareness Week 2023
Quer a matéria completa?
Leia o original em Investor's Business Daily ↗
Politics & Governance